慢性乙型病毒性肝炎治疗现状和展望  

Treatment of chronic hepatitis B infection: status quo and prospect

作　　者：王晶晶[1] 陈国凤[1] 廖家杰 

机构地区：[1]解放军第三0二医院肝硬化诊疗二中心,北京100039 [2]香港天下仁心肠胃及肝脏中心

出　　处：《传染病信息》2017年第2期65-69,74,共6页Infectious Disease Information

基　　金：北京市科委2016年度科技计划重大项目(D161100002716003);国家科技重大专项课题(2013 ZX10002004);北京医学奖励基金资助项目(YJHYXKYJJ-247)

摘　　要：HBV感染是导致肝硬化和肝癌的主要原因,在过去20余年里,慢性乙型肝炎的治疗药物主要为干扰素和核苷(酸)类似物两大类,它们虽然能有效抑制病毒复制,但仍面临HBsAg清除率极低,安全停药难等问题,难以实现"临床治愈(或功能性治愈)"。新型的血清标志物的出现为指导临床如何安全停用抗病毒药物开辟了新的途径,同时,治疗慢性乙型肝炎的新型药物和生物制剂的崛起也给慢性乙型肝炎患者带来福音。HBV infection is the major cause of liver cirrhosis and hepatocellular carcinoma. Over the past two decades, there are currently two classes of drugs approved for the treatment of hepatitis B： a finite antiviral and immunomodulatory treatment with peg-interferon or long-term treatment with nucleos（t） ide analogues.While they can potently suppress the virus replication, they have low rate of HBsAg clearance and common virological relapse after the cessation of therapy. So it is difficult to achieve clinical cure or complete cure. Now appearring of new biomarkers may open the way of stopping nucleos（t） ide analogues clinical use safely. Meanwhile various anti-HBV drugs or biological agents are in the development pipeline, which can bring hope to thousands of hepatitis B patients.

关 键 词：乙型肝炎 治疗 肝炎表面抗原 血清标志物 

分 类 号：R512.62[医药卫生—内科学]